Oasis Pharmaceuticals, LLC

Oasis Pharmaceuticals, LLC is a limited liability company registered in SAM.gov since 2011, located in Lexington, Massachusetts. The company appears to be a biotechnology and pharmaceutical research organization focused on developing innovative drug candidates using proprietary pepducin technology, which targets specific cellular receptors. While limited publicly available background information exists, the company's federal grant award history suggests it specializes in developing novel therapeutic approaches for complex medical conditions using advanced molecular targeting techniques.

The company has been awarded multiple federal grants from prominent health research agencies, including the National Institute of Allergy and Infectious Diseases, National Heart Lung and Blood Institute, and National Cancer Institute. These grants have supported research into developing targeted therapies for conditions like chronic obstructive pulmonary disease (COPD), stroke prevention, and hepatocellular carcinoma. Specifically, Oasis Pharmaceuticals has been developing cell-penetrating lipopeptide compounds called pepducins that target specific receptors such as PAR2 and GPR31. Their research focuses on innovative approaches to interrupt disease progression by targeting molecular pathways involved in inflammation, thrombosis, and cancer cell migration. The grants, ranging from approximately $468,369 to undisclosed amounts, have enabled preclinical studies and development of potential therapeutic agents, often involving collaborations with research institutions like Tufts Medical Center to validate their drug candidates' efficacy and potential clinical applications.